| Nov 8 |
Entera Bio GAAP EPS of -$0.08 misses by $0.03, revenue of $0.04M in-line
|
| Nov 8 |
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 8 |
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
|
| Oct 4 |
Are Medical Stocks Lagging Argenx (ARGX) This Year?
|
| Sep 26 |
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
|
| Sep 25 |
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
|
| Sep 18 |
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
|
| Aug 30 |
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate
|
| Aug 20 |
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
|
| Aug 15 |
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
|
